Bristol-Myers Squibb Co. (BMY)

49.58
0.15 0.30
NYSE : Health Technology
Prev Close 49.43
Open 49.49
Day Low/High 49.21 / 49.73
52 Wk Low/High 42.48 / 63.69
Volume 1.41M
Avg Volume 12.61M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 81.15B
EPS 3.00
P/E Ratio 12.66
Div & Yield 1.64 (3.31%)

Latest News

Bristol‑Myers Squibb Announces Dividend

Bristol‑Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Bristol-Myers Squibb Announces Pooled Five-Year Survival Results For Opdivo (nivolumab) In Previously-Treated Advanced Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb Announces Pooled Five-Year Survival Results For Opdivo (nivolumab) In Previously-Treated Advanced Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb Company (NYSE: BMY) today announced long-term pooled efficacy and safety results from the Phase 3 CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer (NSCLC).

Bristol-Myers Stock Slips After Brain-Cancer-Drug Disappointment

Bristol-Myers Stock Slips After Brain-Cancer-Drug Disappointment

Opdivo failed to show any measurable improvement in patients with a particularly aggressive and rare form of brain cancer compared with patients treated with the current standard of care.

Bristol-Myers Squibb Provides Update On Phase 3 Opdivo (nivolumab) CheckMate -548 Trial In Patients With Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

Bristol-Myers Squibb Provides Update On Phase 3 Opdivo (nivolumab) CheckMate -548 Trial In Patients With Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard of care alone did not...

Https://www.v.org/

Https://www.v.org/

Bristol-Myers Squibb Company (NYSE:BMY) employee Dana Vaughns will celebrate his 10-year anniversary of surviving bone cancer by taking on the physical challenge of his life.

Bristol-Myers Squibb To Take Part At The Morgan Stanley Conference

Bristol-Myers Squibb To Take Part At The Morgan Stanley Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York.

European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone (EPd) For The Treatment Of Patients With Relapsed And Refractory Multiple Myeloma

European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone (EPd) For The Treatment Of Patients With Relapsed And Refractory Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple...

Presage Announces Collaboration With Bristol-Myers Squibb For Phase O Studies Of Novel Cancer Agents Utilizing CIVO™ Technology

Presage Announces Collaboration With Bristol-Myers Squibb For Phase O Studies Of Novel Cancer Agents Utilizing CIVO™ Technology

SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ multiplexed intratumoral microdosing platform, today announced it has entered into a research...

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Jim Cramer weighs in on the U.S.-China trade war and Amgen.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

An Exit, a Purchase, and an Upgrade Monday Morning

We will sell out of one of the most expensive stocks in the portfolio (Shopify) with no yield and redeploy that capital into one of the cheapest in the portfolio with a solid yield (Viacom).

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen will acquire the global rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash, paving the way for Bristol Myers-Squibb to compete its acquisition of Celgene.

Bristol-Myers Squibb Announces Agreement Between Celgene And Amgen To Divest OTEZLA® For $13.4 Billion

Bristol-Myers Squibb Announces Agreement Between Celgene And Amgen To Divest OTEZLA® For $13.4 Billion

Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (NASDAQ: AMGN) under which Amgen would acquire...

Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World

Amgen and Johnson & Johnson Get a Checkup

Jefferies raises its price target for AMGN and judgement day looms for JNJ; here's our take on the health of both companies.

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Building Economic Strength: Cramer's 'Mad Money' Recap (Tuesday 8/20/19)

Jim Cramer says if you want to see the U.S. economy's strength, look to Home Depot, where the consumer's confidence and influence remains healthy.

The Slowdown Stocks: Cramer's 'Mad Money' Recap (Monday 8/12/19)

The Slowdown Stocks: Cramer's 'Mad Money' Recap (Monday 8/12/19)

On a brutal day in an increasingly shaky market, Jim Cramer looks for companies that can meet the the challenges of China, the Fed, or a slowdown.

Stuck in a Rut

The Russell 2000, the Transports and the Bank Index haven’t gone anywhere for around nine months -- until this changes for the better, it’s unlikely the bulls can expect any sort of runaway train on the upside.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

PTC Therapeutics Expands Presence In New Jersey By Securing State-of-the-Art Biologics Facility

PTC Therapeutics Expands Presence In New Jersey By Securing State-of-the-Art Biologics Facility

- Facility will support gene therapy production and continued development of pipeline of investigational medicines -

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

These stocks and sectors are safe havens, and may even be opportunities.

BMY: Insiders Vs. Shorts

BMY: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Bristol-Myers Squibb Co. is the #186 most shorted of the S&P 500 components, based on 4.20 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo® (nivolumab) For The Treatment Of Patients With Untreated Advanced Melanoma

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo® (nivolumab) For The Treatment Of Patients With Untreated Advanced Melanoma

SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.

TheStreet Quant Rating: C+ (Hold)